Literature DB >> 32075365

[Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia].

.   

Abstract

At the end of December 2019, a novel coronavirus (COVID-19) caused an outbreak in Wuhan, and has quickly spread to all provinces in China and 26 other countries around the world, leading to a serious situation for epidemic prevention. So far, there is still no specific medicine. Previous studies have shown that chloroquine phosphate (chloroquine) had a wide range of antiviral effects, including anti-coronavirus. Here we found that treating the patients diagnosed as novel coronavirus pneumonia with chloroquine might improve the success rate of treatment, shorten hospital stay and improve patient outcome. In order to guide and regulate the use of chloroquine in patients with novel coronavirus pneumonia, the multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia developed this expert consensus after extensive discussion. It recommended chloroquine phosphate tablet, 500mg twice per day for 10 days for patients diagnosed as mild, moderate and severe cases of novel coronavirus pneumonia and without contraindications to chloroquine.

Entities:  

Keywords:  Chloroquine; Novel coronavirus pneumonia

Year:  2020        PMID: 32075365     DOI: 10.3760/cma.j.issn.1001-0939.2020.0019

Source DB:  PubMed          Journal:  Zhonghua Jie He He Hu Xi Za Zhi        ISSN: 1001-0939


  47 in total

1.  Chloroquine in fighting COVID-19: good, bad, or both?

Authors:  Daolin Tang; Jingbo Li; Ruoxi Zhang; Rui Kang; Daniel J Klionsky
Journal:  Autophagy       Date:  2020-07-25       Impact factor: 16.016

2.  Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).

Authors:  Nicholas J Mercuro; Christina F Yen; David J Shim; Timothy R Maher; Christopher M McCoy; Peter J Zimetbaum; Howard S Gold
Journal:  JAMA Cardiol       Date:  2020-05-01       Impact factor: 14.676

Review 3.  An update on emerging therapeutics to combat COVID-19.

Authors:  Naveed Nazir Shah; Showkat Ul Nabi; Muzafar Ahmad Rather; Qudratullah Kalwar; Sofi Imtiyaz Ali; Wajid Mohammad Sheikh; Alveena Ganai; Showkeen Muzamil Bashir
Journal:  Basic Clin Pharmacol Toxicol       Date:  2021-06-11       Impact factor: 3.688

Review 4.  Rethinking the role of hydroxychloroquine in the treatment of COVID-19.

Authors:  Eric A Meyerowitz; Augustin G L Vannier; Morgan G N Friesen; Sara Schoenfeld; Jeffrey A Gelfand; Michael V Callahan; Arthur Y Kim; Patrick M Reeves; Mark C Poznansky
Journal:  FASEB J       Date:  2020-04-29       Impact factor: 5.191

Review 5.  New Insights of Emerging SARS-CoV-2: Epidemiology, Etiology, Clinical Features, Clinical Treatment, and Prevention.

Authors:  Gangqiang Guo; Lele Ye; Kan Pan; Yu Chen; Dong Xing; Kejing Yan; Zhiyuan Chen; Ning Ding; Wenshu Li; Hong Huang; Lifang Zhang; Xiaokun Li; Xiangyang Xue
Journal:  Front Cell Dev Biol       Date:  2020-05-22

Review 6.  Treatment algorithm for COVID-19: a multidisciplinary point of view.

Authors:  Felice Galluccio; Tolga Ergonenc; Alvaro Garcia Martos; Abdallah El-Sayed Allam; Maria Pérez-Herrero; Ricardo Aguilar; Giacomo Emmi; Michele Spinicci; Ignacio Terrancle Juan; Mario Fajardo-Pérez
Journal:  Clin Rheumatol       Date:  2020-05-29       Impact factor: 2.980

Review 7.  COVID-19 Drug Treatment in China.

Authors:  Linzi Fan; Shuang Jiang; Xinrong Yang; Zhibin Wang; Chunjuan Yang
Journal:  Curr Pharmacol Rep       Date:  2020-09-07

8.  Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).

Authors:  Nicholas J Mercuro; Christina F Yen; David J Shim; Timothy R Maher; Christopher M McCoy; Peter J Zimetbaum; Howard S Gold
Journal:  JAMA Cardiol       Date:  2020-09-01       Impact factor: 14.676

Review 9.  Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021.

Authors:  Safaet Alam; Taslima Binte Kamal; Md Moklesur Rahman Sarker; Jin-Rong Zhou; S M Abdur Rahman; Isa Naina Mohamed
Journal:  Front Pharmacol       Date:  2021-06-14       Impact factor: 5.810

Review 10.  Coronavirus lockdown helped the environment to bounce back.

Authors:  Shefali Arora; Kanchan Deoli Bhaukhandi; Pankaj Kumar Mishra
Journal:  Sci Total Environ       Date:  2020-06-29       Impact factor: 10.753

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.